<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00208221</url>
  </required_header>
  <id_info>
    <org_study_id>RD 0507/17259</org_study_id>
    <nct_id>NCT00208221</nct_id>
  </id_info>
  <brief_title>Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes</brief_title>
  <official_title>Comparison of a Higher Dose of Ramipril to the Addition of Telmisartan 80 mg+Ramipril 10 mg in Patients With Hypertension and Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Recherches Cliniques de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a dose of ramipril combined with a normal dose&#xD;
      of telmisartan 80 mg will be more effective than ramipril 20 mg in reducing microalbuminuria&#xD;
      in hypertensive patients with diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effects of ramipril 10 mg and telmisartan 80 mg&#xD;
      versus ramipril 20 mg in patients with diabetes type II, hypertension and microalbuminuria&#xD;
      (Urinary-albuminuria creatinine ratio of 2.0 to 25 mg/mmol) on&#xD;
&#xD;
        1. Microalbuminuria&#xD;
&#xD;
        2. Blood pressure (systolic, diastolic and ABPM), Renin-angiotensin system, Catecholamines,&#xD;
           Oxydative stress&#xD;
&#xD;
        3. Comparison at 4, 8 and 12 weeks with addition of hydrochlorothiazide 12.5 mg if BP over&#xD;
           130/80 mmHg&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough recruitment&#xD;
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microalbuminuria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma renin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma angiotensin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma aldosterone</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma catecholamines</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxydative stress</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic blood pressure</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypertension</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Albuminuria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramipril</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramipril-telmisartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female over the age of 18 years&#xD;
&#xD;
          -  Diastolic blood pressure (DBP) greater tha 80 mmHg and less than 104 mmHg&#xD;
&#xD;
          -  Type II diabetes on diet or oral hypoglycemic agents with a hemoglobin A1C (HbA1C)&#xD;
             less than 0.080&#xD;
&#xD;
          -  UA ratio albumin:creatinine 2.0 to 25 mg/mmol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  DBP &gt; 104 mmhg&#xD;
&#xD;
          -  Woman not surgically sterile or menopausal.&#xD;
&#xD;
          -  Premenopausal women whoo are not surgically sterile or who are not practicing&#xD;
             acceptable means of birth control and do not agree to submit to periodic pregnancy&#xD;
             tests.&#xD;
&#xD;
          -  Known or secondary forms of hypertension.&#xD;
&#xD;
          -  Intolerance to angiotensin (AT) 1 receptor blockers or angiotensin-converting enzyme&#xD;
             (ACE) inhibitors.&#xD;
&#xD;
          -  Hepatic or renal dysfunction. Creatinine &gt; 150 umol or enzymes greater than 2 times&#xD;
             upper limit of normal.&#xD;
&#xD;
          -  Hemodynamically significant renal artery stenosis, renal artery stenosis on a solitary&#xD;
             kidney, post-renal transplant or with only one kidney.&#xD;
&#xD;
          -  Uncorrected volume depletion.&#xD;
&#xD;
          -  Biliary obstructive disorders.&#xD;
&#xD;
          -  NYHA functional class congestive heart failure (CHF) III-IV.&#xD;
&#xD;
          -  Coronary heart disease needing pharmacological therapy.&#xD;
&#xD;
          -  Stroke within the preceding six months.&#xD;
&#xD;
          -  Percutaneous transluminal coronary angioplasty (PTCA) within the preceding three&#xD;
             months.&#xD;
&#xD;
          -  History of angioedema.&#xD;
&#xD;
          -  Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevant&#xD;
             cardiac arrhythmias as determined by the clinical investigator.&#xD;
&#xD;
          -  Second or third degree AV block, left bundle branch block or any clinically relevant&#xD;
             conduction abnormality as determined by the clinical investigator.&#xD;
&#xD;
          -  Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant&#xD;
             stenosis of aortic or mitral valve.&#xD;
&#xD;
          -  Administration of digoxin.&#xD;
&#xD;
          -  Patients with a fasting glucose greater than 7.0&#xD;
&#xD;
          -  History of drug or alcohol dependency.&#xD;
&#xD;
          -  Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II&#xD;
             antagonists, alpha-blockers, beta-blockers, calcium channel antagonists, direct&#xD;
             vasodilators that cannot be stopped for the trial.&#xD;
&#xD;
          -  Administration of other non-antihypertensive medications known to affect blood&#xD;
             pressure (e.g. oral corticosteroids, monoamine oxidase [MAO] inhibitors, nitrates) at&#xD;
             any time during the trial.&#xD;
&#xD;
          -  Chronic use of salt substitutes containing potassium chloride; potassium supplements;&#xD;
             extreme dietary restrictions.&#xD;
&#xD;
          -  Uncorrected sodium depletion as defined by a serum sodium level less than 135 mEq/L.&#xD;
&#xD;
          -  Clinically significant hyperkalemia as defined by serum potassium level greater than&#xD;
             5.2 mEq/L. Clinically significant hypokalemia as defined by serum potassium level less&#xD;
             than 3.0 mEq/L.&#xD;
&#xD;
          -  Patients receiving any investigational therapy within one month of signing the&#xD;
             informed consent form.&#xD;
&#xD;
          -  Known hypersensitivity to any component of telmisartan, ramipril or&#xD;
             hydrochlorothiazide.&#xD;
&#xD;
          -  Any other clinical condition which, in the opinion of the principal investigator,&#xD;
             would not allow safe completion of the protocol and safe administration of trial&#xD;
             medication.&#xD;
&#xD;
          -  Blood donation in the preceding 1 month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Larochelle, MD PhD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherches Cliniques de Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Recherches Cliniques de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>J4X 1J3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>November 7, 2007</last_update_submitted>
  <last_update_submitted_qc>November 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2007</last_update_posted>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Microalbuminuria</keyword>
  <keyword>Blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

